JP2022507781A5 - - Google Patents

Info

Publication number
JP2022507781A5
JP2022507781A5 JP2021527836A JP2021527836A JP2022507781A5 JP 2022507781 A5 JP2022507781 A5 JP 2022507781A5 JP 2021527836 A JP2021527836 A JP 2021527836A JP 2021527836 A JP2021527836 A JP 2021527836A JP 2022507781 A5 JP2022507781 A5 JP 2022507781A5
Authority
JP
Japan
Prior art keywords
formula
alkyl
amino acid
compound according
acid residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021527836A
Other languages
English (en)
Japanese (ja)
Other versions
JP7702866B2 (ja
JP2022507781A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/062302 external-priority patent/WO2020106780A1/en
Publication of JP2022507781A publication Critical patent/JP2022507781A/ja
Publication of JP2022507781A5 publication Critical patent/JP2022507781A5/ja
Priority to JP2025106091A priority Critical patent/JP2025138724A/ja
Application granted granted Critical
Publication of JP7702866B2 publication Critical patent/JP7702866B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021527836A 2018-11-20 2019-11-19 Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート Active JP7702866B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025106091A JP2025138724A (ja) 2018-11-20 2025-06-24 Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862769946P 2018-11-20 2018-11-20
US62/769,946 2018-11-20
PCT/US2019/062302 WO2020106780A1 (en) 2018-11-20 2019-11-19 Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025106091A Division JP2025138724A (ja) 2018-11-20 2025-06-24 Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート

Publications (3)

Publication Number Publication Date
JP2022507781A JP2022507781A (ja) 2022-01-18
JP2022507781A5 true JP2022507781A5 (cg-RX-API-DMAC7.html) 2022-11-29
JP7702866B2 JP7702866B2 (ja) 2025-07-04

Family

ID=69005818

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021527836A Active JP7702866B2 (ja) 2018-11-20 2019-11-19 Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート
JP2025106091A Pending JP2025138724A (ja) 2018-11-20 2025-06-24 Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025106091A Pending JP2025138724A (ja) 2018-11-20 2025-06-24 Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート

Country Status (20)

Country Link
US (2) US12209180B2 (cg-RX-API-DMAC7.html)
EP (2) EP3883926B1 (cg-RX-API-DMAC7.html)
JP (2) JP7702866B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210094568A (cg-RX-API-DMAC7.html)
CN (1) CN113382985A (cg-RX-API-DMAC7.html)
AU (1) AU2019384136B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009673A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120528A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001308A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007581A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191430A1 (cg-RX-API-DMAC7.html)
ES (1) ES2984190T3 (cg-RX-API-DMAC7.html)
IL (1) IL283313B2 (cg-RX-API-DMAC7.html)
MA (1) MA53455B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021005822A (cg-RX-API-DMAC7.html)
MY (1) MY206542A (cg-RX-API-DMAC7.html)
PH (1) PH12021551153A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105175WA (cg-RX-API-DMAC7.html)
WO (1) WO2020106780A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103431B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3042428A1 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
CA3120528A1 (en) * 2018-11-20 2020-05-28 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
US12605459B2 (en) * 2020-07-13 2026-04-21 Regeneron Pharmaceuticals, Inc. Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
MX2023004935A (es) 2020-11-10 2023-07-07 Regeneron Pharma Conjugados de anticuerpos y selenio.
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
CA3228214A1 (en) * 2021-11-02 2023-05-11 Changjiang Huang Antibody-drug conjugate intermediate comprising sn38 and preparation method therefor
CN115594766A (zh) * 2021-12-30 2023-01-13 辽宁键凯科技有限公司(Cn) 一种缀合物及用其制备的抗体偶联药物
CN115505028A (zh) * 2022-09-16 2022-12-23 辽宁键凯科技有限公司 一种分支型聚乙二醇连接子及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
EP1239855A4 (en) 1999-12-13 2004-04-21 Merck & Co Inc METHOD FOR PREVENTING AND TREATING ARTERIOSCLEROSIS
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US6908934B2 (en) * 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
EP1398032A1 (en) 2002-09-10 2004-03-17 PheneX Pharmaceuticals AG 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
CA2570496A1 (en) 2004-06-24 2006-01-05 Galapagos N.V. Methods and compositions to promote bone homeostasis
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
US8993628B2 (en) 2007-02-23 2015-03-31 City Of Hope Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
BR112016014126B1 (pt) 2013-12-16 2023-02-14 Medimmune Limited Composto não-peptídico, conjugados de anticorpo-fármaco do mesmo, uso dos ditos conjugados para o tratamento de câncer e composição farmacêutica que compreende os mesmos
SG11201605437YA (en) 2014-01-27 2016-08-30 Pfizer Bifunctional cytotoxic agents
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
US20160324981A1 (en) 2015-05-08 2016-11-10 The California Institute For Biomedical Research Liver x receptor agonists and uses thereof
CA3001938A1 (en) * 2015-11-04 2017-05-11 Borealis Ag A process for producing a multilayer laminate
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
CA3042428A1 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
EP3625209A1 (en) 2017-05-18 2020-03-25 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
CA3120528A1 (en) * 2018-11-20 2020-05-28 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists

Similar Documents

Publication Publication Date Title
JP7754361B2 (ja) 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP7430643B2 (ja) カンプトテシンペプチドコンジュゲート
JP7843731B2 (ja) ビス-オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート
AU2015273098B2 (en) Auristatin derivatives and conjugates thereof
KR20240095316A (ko) Bcma 단일클론 항체 및 항체-약물 접합체
KR20210020015A (ko) 항체에 대한 친화성 물질 및 생체 직교성 관능기를 갖는 화합물 또는 이의 염
JP2023535598A5 (cg-RX-API-DMAC7.html)
US20230405140A1 (en) Anti-cd56 antibody-drug conjugates and their use in therapy
ES2758506T3 (es) Péptidos citotóxicos y conjugados de estos
RU2586885C2 (ru) Цитотоксические пептиды и их конъюгаты антитело-лекарственное средство
JP2022542222A5 (cg-RX-API-DMAC7.html)
JP2017518304A5 (cg-RX-API-DMAC7.html)
JP2020520926A5 (cg-RX-API-DMAC7.html)
JP7702866B2 (ja) Lxrアゴニストとしての使用のためのビス-オクタヒドロフェナントレンカルボキサミド誘導体及びそのタンパク質コンジュゲート
TWI838358B (zh) 疏水性奧瑞他汀(auristatin)f化合物及其結合物
JP2017518359A (ja) 親和性薬物コンジュゲート
IL266202B2 (en) Antibody-conjugated cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide γ receptors
JP2013534528A (ja) 脂質とコンジュゲートする抗体
JP2025510606A5 (cg-RX-API-DMAC7.html)
EP4536283A1 (en) A method for programmatically managing antibody disulfide bonds site-specific modification
KR20250117662A (ko) 단백질 내재화를 위한 조성물 및 방법
JP2019507126A (ja) ツブリシン類似体およびこれらの調製のための方法
JP2024542021A5 (cg-RX-API-DMAC7.html)
JP2024528719A (ja) コンジュゲート化試薬及びそのコンジュゲート
US20260027227A1 (en) Novel thiol reductant, method and use thereof